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Abstract
Systemic lupus erythematosus is a chronic autoimmune disease of complex clinical presentation and etiology and is likely
influenced by numerous genetic and environmental factors. While a large number of susceptibility genes have been
identified, the production of antibodies against a distinct subset of nuclear proteins remains a primary distinguishing
characteristic in disease diagnosis. However, the utility of autoantibody biomarkers for disease sub-classification and
grouping remains elusive, in part, because of the difficulty in large scale profiling using a uniform, quantitative platform. In
the present study serological profiles of several known SLE antigens, including Sm-D3, RNP-A, RNP-70k, Ro52, Ro60, and La,
as well as other cytokine and neuronal antigens were obtained using the luciferase immunoprecipitation systems (LIPS)
approach. The resulting autoantibody profiles revealed that 88% of a pilot cohort and 98% of a second independent cohort
segregated into one of two distinct clusters defined by autoantibodies against Sm/anti-RNP or Ro/La autoantigens, proteins
often involved in RNA binding activities. The Sm/RNP cluster was associated with a higher prevalence of serositis in
comparison to the Ro/La cluster (P=0.0022). However, from the available clinical information, no other clinical
characteristics were associated with either cluster. In contrast, evaluation of autoantibodies on an individual basis revealed
an association between anti-Sm (P=0.006), RNP-A (P=0.018) and RNP-70k (P=0.010) autoantibodies and mucocutaneous
symptoms and between anti-RNP-70k and musculoskeletal manifestations (P=0.059). Serologically active, but clinically
quiescent disease also had a higher prevalence of anti-IFN-a autoantibodies. Based on our findings that most SLE patients
belong to either a Sm/RNP or Ro/La autoantigen cluster, these results suggest the possibility that alterations in RNA-RNA-
binding protein interactions may play a critical role in triggering and/or the pathogenesis of SLE.
Citation: Ching KH, Burbelo PD, Tipton C, Wei C, Petri M, et al. (2012) Two Major Autoantibody Clusters in Systemic Lupus Erythematosus. PLoS ONE 7(2): e32001.
doi:10.1371/journal.pone.0032001
Editor: Michael P. Bachmann, Carl-Gustav Carus Technical University-Dresden, Germany
Received October 27, 2011; Accepted January 17, 2012; Published February 21, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by the Division of Intramural Research, National Institute of Dental and Craniofacial Research. This study was also supported
by the National Institute of Arthritis and Musculoskeletal and Skin Diseases R01 AR043727 (MP), U19AI56390 (IS) and R37 AI049660-06A1 (IS). The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ching.kathryn@gmail.com
¤ Current address: U.S. Department of Agriculture, Albany, California, United States of America
Introduction
Systemic lupus erythematosis (SLE) is an autoimmune inflam-
matory disease characterized by interferon and complement
activation, autoantibodies, and tissue destruction involving multi-
ple organ systems [1]. In addition, activation of type I interferons is
also prevalent in SLE and may be associated with distinct
autoantibody profiles [2]. Common clinical symptoms in SLE
include rash, nephritis, central nervous system disease, thrombo-
cytopenia and musculoskeletal manifestations. SLE often occurs in
women between 20–40 years of age and has strong genetic and
environmental components [3,4,5]. Despite genetic studies
identifying a large number of susceptibility genes including key
immunological regulators, such as BANK1, TNFAIP3, ITGAM,
PD1 and STAT4 [5,6,7], exploiting this information for
identifying and stratifying clinical subsets of SLE has been largely
unsuccessful. The use of genetic markers to identify and stratify
clinical subsets is hampered by genetic complexity and the high
frequency of many of the SLE susceptibility alleles in the general
population.
In contrast to genetic analyses, autoantibodies represent a major
diagnostic feature of SLE and can provide clues to pathological
processes in various tissues. Although a very large number of
autoantibodies have been described in SLE [8], only anti-double
stranded DNA (dsDNA), Smith (Sm) and phospholipid (PL)
autoantibodies are part of the classification criteria outlined by the
American College of Rheumatology, although it should be noted
that anti-PL (aPL) autoantibodies are not specific for SLE [9].
Similarly, other major nuclear and cytoplasmic target antigens,
including several ribonuclear proteins (RNP), the RNA binding
proteins Ro52 and Ro60 and the 48 kDa protein La, while
prevalent in SLE, are not specific for the disease. In recent years, a
significant effort has been directed at understanding the
relationship between autoantibody profiles and specific disease
subsets. For example, in one study, anti-Ro and anti-La
autoantibodies, which are prevalent in Sjogren’s Syndrome, were
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and eyes [10,11]. Anti-La autoantibodies have also been associated
with less severe disease and a reduced risk of lupus nephritis [12].
Autoantibodies against Sm and RNP are often found together and
were associated with a higher incidence of Raynaud’s syndrome
and leukopenia [10]. Lupus anticoagulant (LAC) and anti-
cardiolipin (cL) antibodies have been observed to correlate with
an increased risk of venous thrombosis [13]. The numerous and
often inconsistent clinical associations reported for autoantibodies
observed in lupus may reflect differences in method of detection
and composition of the patient cohort. These and other findings
suggest that further improvements in SLE antibody profiles
including quantitative assessment of autoantibody titers, increasing
the spectrum of targets examined, and assay simplification might
lead to improved diagnosis, classification, therapeutic intervention,
and prognosis.
To test whether high resolution profiling of lupus autoantibodies
would provide data for clinically informative clustering, a solution
phase assay format called luciferase immunoprecipitation assay
systems (LIPS) was used. LIPS employs the light emitting Renilla
luciferase (Ruc) enzyme genetically fused to potential protein or
peptide antigens. This provides a uniform platform for detection of
autoantibodies against various tagged proteins. LIPS is quantita-
tive, linear up to 7 log units, and in previous studies in several
different autoimmune conditions yielded higher sensitivity and
specificity and/or a larger dynamic range than existing ELISA or
radiobinding assays [14].
In this study, a pilot and second cohort of SLE patients and
control serum samples were evaluated against a panel of
autoantigens including seven nuclear antigens, five cytokines,
and five CNS-enriched proteins. We also evaluated a potentially
new test for lupus autoantibodies by combining six of the major
autoimmune targets into one assay. Analysis of the autoantibody
profiles, in conjunction with available clinical information,
revealed several associations between autoantibodies and specific
clinical manifestations. We also observed a high frequency of anti-
IFN-v autoantibodies in the SLE cohort, which correlated with
high titer anti-Sm, anti-RNP-A and anti-RNP-70k autoantibodies.
Additionally, we identified two distinct patient clusters based on
titer ratios that dichotomize the population with at least one
clinical symptom, serositis, clearly associating with the validation
cohort. The data presented suggest multifactorial roles for
autoantigens in lupus, and emphasize the need for further
refinements in autoantibody testing and more intensive profiling
in order to more thoroughly understand and treat this disease.
Materials and Methods
Ethics Statement
Serum samples from SLE patients and healthy volunteers were
obtained from the Department of Rheumatology, University of
Rochester Medical Center and the Division of Rheumatology,
The Johns Hopkins University School of Medicine. All studies
were conducted, and all samples were obtained with written,
informed consent under Institutional Review Board approved
protocols from the University of Rochester Medical Center and
The Johns Hopkins Medical Center.
Patients and serum samples
All SLE patients fulfilled at least four of the American College of
Rheumatology criteria for diagnosis. The initial training set
consisted of 18 healthy volunteers and 76 SLE patients. The
independent validation cohort consisted of 15 new healthy controls
and 129 SLE patients. Sera were stored at 280uC, then diluted
1:10 in buffer A (50 mM Tris (pH 7.4), 100 mM NaCl, 5 mM
MgCl2, 1% Triton X-100 and a protease inhibitor cocktail
(Roche)) and stored at 220uC prior to use.
Generation and expression of Ruc-antigen fusion
proteins
Several Renilla luciferase (Ruc) C-terminal fusion proteins
representing known SLE targets including Ro52, Ro60 and La
have been previously described [15,16]. The GenBank accession
numbers and exact amino acids (aa) used for these target antigens
are as follows: La (NP_003133.1; aa 2–408), Ro52 (NP_003132.2 ;
aa 2–276), Ro60 (NP_004591.2|; aa 244–538), Sm-D3
(NP_004166.1|; aa 2–126), snRNP A1 (NP_004587.1|; aa 1–
282, referred to as RNP-A in the manuscript), snRNP 70k
(NP_003080| ; aa 1–437, referred to as RNP-70k in the
manuscript), histone 2B (NP_003514.2; aa 1–126), Interferon-a
(NP_076918.1|; aa 24–189), Interferon-l (NP_742152.1|; aa 20–
200), Interferon-v (NP_002168.1| ; 24–195), Interferon-c
(NP_000610.2|; aa 24–166), GMCSF (NP_000749.2|; aa 15–
144), GAD65 (NP_000809.1|; aa 1–585), aquaporin-4
(NP_001641.1|; aa 2–323), tyrosine hydroxylase (NP_000351.2|;
aa 2–497) and glial fibrillary acidic protein (NP_002046.1|; aa 2–
432). All antigens used in this study were cloned in-frame between
BamH1 and Xho1 sites in the previously described pREN2 vector
containing an N-terminal FLAG epitope tag [17]. The primer
adaptor sequences used to amplify these genes are provided in
Table S1. DNA midiprep DNA for each plasmid construct was
then prepared (Qiagen) and the correct sequence in each plasmid
was confirmed by DNA sequencing.
Six of the major SLE Ruc-antigen fusion proteins (La, Sm-D3,
Ro52, Ro60, RNP-A, RNP-70k) produced from transfected
mammalian cells were also analyzed by Western blot. Production
of Ruc-antigens involved using COS1 cells that were maintained
at 5% CO2,3 7 uC in high glucose DMEM (HyClone) supple-
mented with 10% fetal calf sera and 2 mM L-glutamine. For
recombinant protein expression, COS1 cells were transfected with
a mixture of 1–2 mg of each pREN2-antigen plasmid along with
FuGENE 6 (Roche) reagent as previously described [18]. Forty-
eight hours after transfection, tissue culture media was removed
and the cell layer harvested in SDS PAGE sample buffer. The
proteins were resolved by 4–12% Tris-Glycine PAGE electropho-
resis and then electrotransfered to nitrocellulose. Following
blocking with bovine serum albumin, a horseradish peroxidase-
conjugated anti-FLAG monoclonal antibody (Sigma) was used to
directly detect the FLAG-tagged Ruc-antigens by enhanced
chemiluminescence (ECL) reagents (Figure S1). Western blotting
revealed that all six Ruc-antigen fusion proteins migrated at their
predicted molecular weight and appeared intact with little
evidence of proteolytic processing.
For production of Ruc-antigen fusion proteins for LIPS, the
same transfection protocol was followed. However for harvesting
the Ruc-antigen fusion, the COS1 cells were first rinsed in PBS
and then scrapped in 1.4 ml of cold lysis buffer composed of
50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 1% Triton
X-100, 50% glycerol and protease inhibitors (Mini protease
inhibitor cocktail, Roche). The cell lysate was sonicated,
centrifuged and the cleared supernatants were collected and used
immediately or stored at 280uC as described [18].
LIPS analysis
LIPS was performed in a 96-well plate format as described [18].
For each test, 1 mL equivalent of serum was used. Additional sera
dilutions were required for anti-Ro60 assays. Plates were washed
on a Tecan Hydroflex (Tecan Systems, San Jose, CA), and light
Autoantibody Clusters in SLE
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e32001units (LU) were measured in a Berthold LB 960 Centro
luminometer (Berthold Technologies, Germany) using coelenter-
azine mix (Promega, Madison, WI). Light unit data were the
average of at least two independent experiments.
Statistical analysis
GraphPad Prism software (San Diego, CA) was used for statistical
analysis. Mann-Whitney U-tests were used to compare antibody
titers among the different clusters. Cutoffs for sensitivity and
specificity were determined using optimal separation based on
receiver operator characteristics (ROC). Fisher’s exact test was
employed to evaluate differences inautoantibody frequency between
clusters.
Heatmap assembly and determination of autoantibody
enriched clusters
To compare autoantibody titers between different antigens, a
colored heatmap based on the Z score of each titer was employed.
First, a cutoff was calculated based on the mean plus three
standard deviations of the seronegative healthy controls for each
antigen. This cutoff was subtracted from the autoantibody titer
measured for each patient, and the resulting value was divided by
the standard deviation of the control cluster to yield the Z score.
Patients were then color coded by the number of standard
deviations above the calculated cutoff.
Results
Detection of autoantibodies against the major SLE
antigens by LIPS
Based on the fact that solution phase immunoassays provide
more discriminatory quantitative antibody profiles than solid
phase ELISA [14,19], a panel of seven, known nuclear and
extractable SLE antigens produced in mammalian cells was
evaluated in a pilot cohort of 76 SLE patients and 18 healthy
controls. These antigens included Sm-D3, RNP-A, RNP-70k,
histone 2B, La, Ro52 and Ro60. For each antigen, the optimal
separation between the SLE and control groups were determined
using Receiver Operator Characteristics (ROC) and the sensitivity
and specificity was calculated (Table 1). The dynamic range (95%
CI) and the statistical difference (Mann Whitney U test) was
determined for each antigen between the SLE and control samples
(Table 1). From LIPS testing, antibodies against the RNP-70k
antigen demonstrated the greatest sensitivity in the antigen panel
with 71% sensitivity and 94% specificity (Table 1). The related
RNP-A protein was only 59% sensitive (94% specific), and
detected SLE patients who were all also seropositive for RNP-70k
autoantibodies by LIPS. Detecting antibodies against the Sm
antigen in SLE also showed a sensitivity of 59% and a specificity of
94%. Analysis of autoantibodies against Ro52 and Ro60,
comprising the SSA antigen, using immunodominant protein
fragments from each protein demonstrated 50% and 57%
sensitivity, respectively and autoantibodies against SSB/La were
Table 1. LIPS diagnostic autoantibody characteristics in SLE.
Sensitivity (%) Specificity (%) Mean titer HC (95% CI) Mean titer SLE (95% CI) P
Core SLE antigens
Ro52 50 89 90,000 (255,00–236,00) 408,000(251,000–565,000) ,0.001
{
Ro60 57 83 178,000 (2169,000–525,000) 898,000(609,000-1.2610
6) 0.0019
{
La 49 83 126,000 (2104,500–356,000) 265,000 (100,000–430,000) 0.0193
{
Sm 59 94 3,000 (2,000–4,200) 26,000 (9,500–42,000) ,0.0001
{
RNP-A 59 94 16,000 (2,100–29,000) 121,000 (39,000–203,000) ,0.0001
{
RNP-70k 71 94 7,900 (5,000–11,000) 103,000 (69,000–137,000) ,0.0001
{
Histone 2B 42 89 22,000 (17,000–27,000) 50,000 (39,000–61,000) 0.0047
{
Overall sensitivity of core
antigens*
88 72
Interferons
IFN-a 13 94 1,600 (1,300–1,900) 2,900 (1,500–4,200) 0.1118
IFN-v 29 100 2,600 (2,400–2,700) 7,400 (285–15,000) 0.0030
{
IFN-l 17 100 19,000 (17,000–22,000) 66,000 (214,000–146,000) 0.0345
{
IFN-c 10 94 7,200 (5,200–9,100) 7,500 (5,800–9,200) 0.5708
Overall prevalence of
anti-IFN antibodies
42 94
Neuronal proteins
GAD65 30 89 2,500 (2,000–3,000 5,000 (3,500–6,500) 0.0739
AQP-4 12 94 4,900 (3,100–6,700) 9,400 (4,900–14,000) 0.1441
TH 30 89 5,000 (2,000–8,000) 10,000 (5,100–15,000) 0.1739
GFAP 16 100 13,000 (10,800–15,000) 22,000 (16,000–28,000) 0.0763
Overall prevalence of
anti-neuronal antibodies
47 77
*Excluding Histone 2B.
{Statistically significant, P,0.05.
doi:10.1371/journal.pone.0032001.t001
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assay, anti-histone 2B autoantibodies were the least sensitive,
detecting only 42% of the SLE patients, but did not add to the
overall diagnostic performance because seropositive patients were
already positive for at least one of the other nuclear antigens by
LIPS. Overall, a six antigen panel consisting of Sm-D3, RNP-A,
RNP-70k, La, Ro52 and Ro60 detected at least one statistically
significant SLE antibody in 88% (67/76) of this SLE pilot cohort.
As shown in Table 1, LIPS profiling of antibodies against these
antigens demonstrated large dynamic ranges of detection, which
were often 10–200 fold higher in SLE compared to the normal
controls. These findings suggest that LIPS provides highly
discriminatory detection of antibodies for SLE diagnosis and
potentially even for disease stratification and symptoms research.
Anti-interferon and anti-neuronal autoantibodies in
Lupus patients
Based on our previous ability to detect anti-cytokine and
neuronal autoantibodies in other diseases by LIPS [16,20,21], a
select panel of Ruc-antigen fusion proteins was evaluated in the
pilot cohort. Screening for autoantibodies against 4 different
interferon proteins including IFN-a, IFN-l, IFN-v, and IFN-c
revealed statistically significant autoantibodies to all four interfer-
ons in SLE patients compared to controls (Table 1). Anti-IFN-v
autoantibodies were the most common, and were detected in 29%
(22/76) of patients (Table 1). In contrast, anti-IFN-l, anti-IFN-a
and anti-IFN-c autoantibodies were seropositive in fewer patients
with sensitivities of 17%, 13% and 10%, respectively. Additional
screening for other cytokines revealed only a few low titer
autoantibodies in SLE patients (e.g. anti-GMCSF autoantibodies
in 4% of the SLE patients). Of note, several individual SLE
patients showed quite high titer anti-interferon autoantibodies that
were 100 times higher than the control group. Overall, 42% (32/
76) of patients demonstrated reactivity toward at least one
interferon. These results also suggest that anti-IFN-v and other
anti-interferon autoantibodies are quite common in SLE.
Autoantibody responses were also evaluated against a number
of neurological antigens, including glutamic acid decarboxylase
(GAD-65), aquaporin-4 (AQP-4), tyrosine hydroxylase (TH) and
glial fibrillary acidic protein (GFAP). Seropositive autoantibody
responses against GAD-65 and TH autoantigens were the most
frequent, occurring in 30% of the SLE patients (Table 1). Anti-
GFAP and anti-AQP4 autoantibodies were less common, and
were detected in 16% and 12% of patients, respectively. The
calculated specificity of these LIPS antigen tests ranged between
89% and 100%, demonstrating that these neuronal autoantibodies
are rarely found in the healthy controls. Overall, almost half of the
SLE patients (36/76, 47%) had autoantibodies against this panel
of four neuronal antigens.
Two major autoantibody clusters in SLE
To see if particular clusters or patterns of autoantibodies were
present, a colored heat map based on the Z score of each antibody
titer above the mean of the seronegative control samples was used
to compare autoantibody titers between different antigens in the
different patients in the pilot cohort (Fig. 1). Following the
generation of this antibody titer-based heatmap, two major
patterns emerged. One subset of patients showed immunoreactiv-
ity predominately to Sm-D3, RNP-A or RNP-70k, but less
pronounced or no immunoreactivity at all against Ro52, Ro60 or
La proteins. Conversely, a second subset showed a dominant
pattern of reactivity against Ro52, Ro60 and/or La autoantigens,
but had significantly less or no immunoreactivity against Sm-D3,
RNP-A or RNP-70k. Interestingly, some patients within these
groups were mutually exclusive of each other. For example, 14%
(11/76) of the SLE patients showed pure Sm/RNP reactivity
without immunoreactivity against Ro or La antigens, while 17%
(13/76) of the SLE patients demonstrated a pure Ro/La reactivity
without immunoreactivity against Sm, RNP-A or RNP-70k (Fig. 1).
To further segregate the patients with a mixed Sm/RNP and Ro/
La autoantibody phenotype, a straightforward algorithm was
utilized. For determining cluster assignment, the relative ratio
(RR) of autoantibody titers against the sum titer of Sm-D3, RNP-A
and RNP-70K was compared to the sum titer for Ro52, Ro60 and
La, whereby patients with RR$1 were assigned to a Sm/RNP
cluster, while patients with a RR,1 were assigned to a Ro/La
cluster. Based on these criteria, 41% (31/76) of the SLE samples
showed a Sm/RNP cluster phenotype, while 47% (36/76) showed
a Ro/La phenotype (Fig. 1). Additionally, a small subset of SLE
patients (12%, 9/76) displayed no significant seropositive autoan-
tibody responses to any of these 6 antigens tested. Further analysis
of these autoantibody groups using Fisher’s exact test revealed no
Figure 1. SLE autoantibody clusters in the pilot cohort. A
colored heat map was used to visualize the autoantibody titers in the
SLE patients. Autoantibody titers were transformed to Z scores as
described in the Materials and Methods and color coded as indicated by
the scale at right, in which signal intensities from green to black
indicate high and low titers, respectively. To segregate the SLE patients
into clusters, the relative ratio (RR) of the sum titer of Sm-D3, RNP-A and
RNP-70k divided by the sum titer of Ro52, Ro60 and La autoantibodies
was calculated for each patient. Patients with a RR$1 were assigned to
the Sm/RNP cluster (top panel) while patients with a RR,1 were
assigned to the Ro/La cluster (bottom panel). Patients with a pure Sm/
RNP or pure Ro/La phenotype are indicated.
doi:10.1371/journal.pone.0032001.g001
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antibodies between the Sm/RNP and Ro/La clusters (data not
shown). Taken together, these results suggest that 88% of the SLE
patients from the pilot cohort show either a prominent Sm/RNP
or Ro/La autoantibody cluster phenotype.
Two major autoantibody clusters and other
autoantibodies in a second SLE cohort
To determine if the two major autoantibody clusters identified
in the pilot cohort showed a relationship with documented clinical
symptoms, a new independent cohort consisting of 15 controls and
129 SLE patients was obtained. The new cohort had female to
male ratio of 13:1, and the average age at diagnosis was 31612.1
years. Similar to other published studies with SLE patients, the
most frequent clinical manifestations in this SLE cohort were
musculoskeletal symptoms (37%) and mucocutaneous symptoms
(36%). Eleven patients (9%) were classified as serologically active
but clinically quiescent, and eleven patients (9%) were classified as
quiescent. Evaluation of six of the major SLE antigens (RNP-A,
RNP-70k, Sm-D3, La, Ro52 and Ro60) with LIPS disclosed a
wide dynamic range of detectable antibody titers with significant
differences in the GMTs for each antigen between the SLE
patients and the control group (Table 2). Anti-RNP-70k
autoantibodies again showed the highest sensitivity and detected
autoantibodies in 85% of SLE patients. Anti-Sm and anti-La
autoantibodies were detected in 65% and 71% of the SLE
patients, respectively (Table 2) and anti-Ro52 and anti-Ro60
autoantibodies were each found in 51% of the SLE patients (100%
specificity).
Similar to the pilot cohort, a colored heat map based on the Z
score of each antibody titer data in the second SLE cohort also
showed the two major autoantibody clusters. Using the segregation
algorithm developed for the pilot cohort, we observed in the
validation cohort that 47% (61/129) of the SLE samples showed a
Sm/RNP cluster phenotype, 51% (66/129) showed a Ro/La
cluster phenotype and 2% (2/129) displayed no significant
autoantibody responses to any of the antigens tested (Fig. 2).
Using the Fisher’s exact statistical test, the frequency of six disease
manifestations, including nephritis, serositis and musculoskeletal,
mucocutaneous, hematologic and CNS symptoms, were compared
between the two clusters (Table 3). Surprisingly, the only
significant difference between the two clusters was the frequency
of serositis, inflammation occurring in serous membranes
surrounding body organs, which correlated with the Sm/RNP
cluster (P=0.0022). Furthermore, analysis of the two clusters
revealed that there were no differences in the proportion of SACQ
or quiescent patients and no difference in the average SLEDAI
score.
The frequency of IFN and neuronal protein targets were also
evaluated by autoantibody cluster. Within the entire cohort, anti-
IFN-v autoantibodies were the most prevalent (38%) and anti-
IFN-a autoantibodies were observed in only 12% of patients. With
the exception of GFAP, the other neurological antigens were less
commonly detected in this second group compared to the pilot
cohort (Table 2). Anti-TH autoantibodies were observed in 8% of
patients, while anti-AQP4 and anti-GAD65 autoantibodies were
each only observed in 5% of patients. By cluster, however, there
were no significant differences in the frequency of anti-neuronal
and anti-IFN autoantibodies between patients with Sm/RNP or
Ro/La cluster phenotype (Table 3).
Correlation of clinical characteristics with autoantibody
titers
In addition to analyzing clinical correlations between the two
identified autoantibody clusters, individual autoantigens were also
inspected to evaluate whether they correlated with clinical
symptoms. While many autoantibodies did not correlate with
particular clinical symptoms (Table 4), anti-RNP-70k autoanti-
bodies were found to be more prevalent in patients with
musculoskeletal manifestations than those without symptoms
(Fisher’s exact test 94% v. 79%; P=0.059). Patients with
mucocutaneous manifestations were also more frequently observed
with anti-Sm (81% v. 56%; P=0.007), anti-RNP-A (68% v. 46%;
P=0.01) and anti-RNP-70k (96% v. 78%; P=0.01) autoantibod-
Table 2. Sensitivity and specificity of Ruc-antigen fusions in an independent validation cohort.
Sensitivity (%) Specificity (%) Mean titer HC (95% CI) Mean titer SLE (95% CI) P
Core SLE antigens
Ro52 51 100 10,000 (6,000–14,000) 895,000 (636,000-1.1610
6) ,0.0001
{
Ro60 51 100 5,000 (3,400–7,200) 1.2610
6 (915,000-1.5610
6) 0.0004
{
La 71 93 4,700 (3,300–6,100) 464,000 (294,000–634,000) ,0.0001
{
Sm 65 100 4,800 (4,200–5,400) 77,000 (49,000–105,000) ,0.0001
{
RNP-A 55 100 12,600 (8,200–17,000) 276,000 (212,000–339,000) 0.0017
{
RNP-70k 85 100 28,800 (24,800–32,800) 559,000 (440,000–678,000) ,0.0001
{
Overall sensitivity of core antigens 98% 93%
Cytokines
IFN-a 12 100 2,000 (1,600–2,500) 88,000 (66–175,000) 0.0686
IFN-v 38 100 1,900 (1,700–2,000) 7,800 (2,500–13,000) 0.0003
{
Neuronal proteins
AQP-4 5 93 10,600 (2,000–19,000) 27,000 (29,100–62,000) 0.7162
GAD65 5 93 4,300 (2,700–6,000) 4,200 (3,200–5,300) 0.7951
GFAP 17 100 7,700 (5,100–10,000) 21,000 (2,200–40,000) 0.1930
TH 8 93 11,600 (3,700–20,000) 15,000 (10,200–20,000) 0.2841
doi:10.1371/journal.pone.0032001.t002
Autoantibody Clusters in SLE
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32001ies in comparison to those without these symptoms. Interestingly,
analysis of the anti-IFN-v within the cohort at large revealed that
IFN-v seropositive SLE patients were more likely to have positive
anti-Sm (Fisher’s exact test, 80% v. 56%; P=0.0079) and anti-
IFN-a (22% v. 5%; P=0.0041) autoantibodies compared to IFN-
v seronegative SLE patients. Moreover, the GMT of anti-Sm
autoantibodies was also significantly higher in the anti-IFN-v
positive group (Student’s t-test, P=0.0037). Anti-IFN-a autoanti-
bodies were observed in only 12% of patients and were more
common in female v males (Fisher’s exact test, 44% v. 9%;
P=0.0108).
Eleven of 129 patients in the second cohort were classified as
SACQ, a subgroup of SLE defined as having clinically quiescent
symptoms despite increased anti-dsDNA and/or low serum
complement levels using conventional clinical assays. While there
was no difference in the frequency of seropositivity for anti-IFN-v
autoantibodies between the patients with and without SACQ
classification, the SACQ patients had a significantly higher
frequency of anti-IFN-a autoantibodies, with 4/11 seropositive
(36% v. 9%; P=0.024) (Table 4). Together these results suggest
that the SACQ patient subgroup has a unique autoantibody
profile that may play a role in their relatively less severe clinical
symptoms. Interestingly, there was a lower frequency in Ro52,
Sm-D3, RNP-A and RNP-70k seropositivity in the quiescent
group compared to the rest of the cohort (Table 4).
Autoantibody profiles were also evaluated among the different
SLE ethnic and age groups. From this analysis, African-American
SLE patients were more frequently positive for anti-Sm (76% v.
54%; P=0.0187) and anti-RNP-A (75% v. 37%; P=0.0001)
autoantibodies compared to Caucasians (Table 5). Overall, the
African Americans showed larger number of samples belonging to
the cluster 1 enriched phenotype compared to the Caucasians, but
the difference was not statistically significant (data not shown).
Anti-IFN-v autoantibodies were also most prevalent in African
Americans SLE patients compared to both Caucasians (54% v.
29%; P=0.0131) and Asians (54% v. 0; P=0.024). Autoantibody
profiles were also examined by age group. Middle age range
patients (20–40 years of age) were more frequently positive for
anti-RNP-A autoantibodies compared to those .40 years of age
(60% v. 34%; P=0.0280), and more frequently positive for anti-
Ro52 autoantibodies than individuals less than 20 years of age
(61% v. 36%; P=0.0368) and greater than 40 years of age (61% v.
37%; P=0.0472) (Table 6).
Lastly, we also examined whether the frequency of the major
SLE autoantibodies correlated with dsDNA autoantibody status.
Using the standard clinical assay, 58% (75/129) of SLE patients in
the cohort were positive for anti-dsDNA autoantibodies. Anti-
dsDNA positive patients were more frequently positive than
seronegative patients for anti-Sm (73% v. 53%; P=0.022), anti-
Ro60 (61% v. 35%; P=0.006) and anti-La (79% v. 61%;
P=0.0428) autoantibodies (Table 7). Additionally, anti-IFN-v
(48% v. 24%; P=0.0085) and anti-TH (12% v. 2%; P=0.048)
autoantibodies were all more prevalent in patients with dsDNA
Figure 2. Validation of two major autoantibody clusters in SLE.
A second SLE cohort was analyzed for autoantibody titers. A heatmap
was again constructed and antibody clusters were determined as in
Figure 1. Similar to the prevalence seen in the first cohort, 47% of the
SLE samples showed a Sm/RNP cluster phenotype and 51% showed a
Ro/La cluster phenotype.
doi:10.1371/journal.pone.0032001.g002
Table 3. Percentage of patients in each cluster with specific
clinical manifestations and autoantibodies.
Ro/La Sm/RNP P
Clinical Symptoms
CNS 7 2 0.20
Musculoskeletal 30 44 0.09
Mucocutaneous 39 33 0.58
Nephritis 37 25 0.18
Serositis 0 13 0.002
Hematological 18 13 0.47
SACQ 7 10 0.75
Quiescent 4 13 0.11
Autoantibodies
IFN-a 6 17 0.06
IFN-v 41 35 0.59
TH 8 10 0.76
AQP-4 5 5 1.0
GAD65 2 6 0.20
GFAP 15 17 0.81
doi:10.1371/journal.pone.0032001.t003
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CNS Musculoskeletal Mucocutaneous Nephritis
2 + P 2 + P 2 + P 2 + P
Sm 64 83 0.66 59 75 0.08 56 81 0.007 64 68 0.69
RNP-A 53 83 0.21 51 60 0.36 46 68 0.01 55 54 1.0
RNP-70k 85 83 1.0 79 94 0.02 78 96 0.01 81 93 0.11
Ro52 50 67 0.68 52 50 0.85 48 57 0.36 47 59 0.26
Ro60 50 83 0.21 57 42 0.10 50 53 0.85 45 63 0.06
La 71 83 0.67 73 69 0.68 70 74 0.69 69 76 0.53
IFN-a 12 0 1.0 1 14 0.57 12 11 1.0 15 5 0.14
IFN- v 37 50 0.67 38 37 1.0 37 38 1.0 34 46 0.24
TH 9 0 1.0 11 4 0.32 11 4 0.33 6 15 0.10
AQP-4 5 0 1.0 5 4 1.0 5 4 1.0 5 5 1.0
GAD65 3 16 0.22 2 6 0.36 5 2 1.0 5 2 1.0
GFAP 15 50 0.06 20 10 0.22 20 11 0.22 14 22 0.30
Hematological SACQ Quiescent
2 + P 2 + P 2 + P
Sm 65 65 1.0 67 45 0.19 67 36 0.04
RNP-A 53 60 0.63 56 36 0.34 58 18 0.02
RNP-70k 83 90 0.73 86 64 0.06 88 45 0.002
Ro52 48 65 0.22 53 27 0.12 54 18 0.02
Ro60 48 65 0.22 52 45 0.76 53 27 0.12
La 70 75 0.79 73 86 0.29 73 55 0.29
IFN-a 12 10 1.0 9 36 0.02 12 9 1.0
IFN- v 38 35 0.80 36 45 0.53 38 27 0.53
TH 9 5 1.0 8 9 1.0 9 0 0.59
AQP-4 5 5 1.0 5 0 1.0 5 0 1.0
GAD65 5 0 1.0 4 0 1.0 4 0 1.0
GFAP 17 10 0.53 16 18 1.0 15 27 0.38
doi:10.1371/journal.pone.0032001.t004
Table 5. Percentage of seropositive patients by ethnicity.
CA A A P
Sm 54 76 83 0.01
*
RNP-A 37 75 66 0.0001
*
RNP-70k 78 90 100
Ro52 53 54 50
Ro60 45 54 67
La 63 79 83
IFN-a 14 12 0
IFN-v 29 54 0 0.01
*, 0.02
**
TH 6 8 17
AQP-4 5 6 0
GAD65 3 4 17
GFAP 11 23 0
C: Caucasian; AA: African American; A: Asian. Significant differences in the
frequency of autoantibody titers:
*White v. African American;
**African American v Asian.
doi:10.1371/journal.pone.0032001.t005
Table 6. Percentage of seropositive patients by age group.
,20 20–40 .40 P
Sm 72 69 48
RNP-A 60 60 34 0.028**
RNP-70k 88 85 79
Ro52 36 61 37 0.037*, 0.047**
Ro60 44 57 41
La 80 75 55
IFN-a 16 9 14
IFN-v 52 36 31
TH 24 4 7 0.007*
AQP-4 4 5 3
GAD65 8 1 7
GFAP 12 20 10
Significant differences in the frequency of autoantibody titers:
*,20 v. 20–40;
**20–40 v. .40.
doi:10.1371/journal.pone.0032001.t006
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suggest that SLE patients seropositive for Sm, Ro60, La, INF-v
and anti-TH autoantibodies are also often seropositive for anti-
dsDNA.
A simple LIPS mixture test for SLE diagnosis
One major advantage of LIPS is the ability to test mixtures of
antigens, which simplifies data collection and often improves the
overall performance of the assay [22,23]. Based on the results from
the individual LIPS tests for the six different nuclear antigens, a
mixture format using the 6 autoantigen panel of Sm-D3, RNP-A
and RNP-70k, Ro52, Ro60, and La was evaluated with 1 mLo f
serumfromthedifferentclinicalsamples.Theresults oftesting using
the mixture demonstrated 83% sensitivity and 93% specificity for
cohort2 (Fig. 3).Asfoundwithtesting theautoantigensindividually,
one healthy control was seropositive in the mixture format and this
was most likely due to high anti-La antibody titers (data not shown).
Comparison of the mixture results with the sum of the individual
antibody titers determined previously revealed that the titer values
strongly correlated (Spearman Rank R=0.95 (Fig. 3). These results
suggest that the LIPS mixture format is comparable to the
individual antibody tests and thus provides a simplified format for
the detection of SLE autoantibodies.
Table 7. Percentage of seropositive patients by anti-dsDNA
antibody status.
2 + P
Sm 53 73 0.022
RNP-A 45 61 0.100
RNP-70k 78 89 0.127
Ro52 43 59 0.103
Ro60 35 61 0.006
La 61 79 0.043
IFN-a 10 12 0.779
IFN-v 24 48 0.008
TH 2 12 0.048
AQP-4 8 3 0.221
GAD65 4 4 1.0
GFAP 16 16 1.0
doi:10.1371/journal.pone.0032001.t007
Figure 3. Comparison of LIPS mixture test with the sum of the individual tests for SLE diagnosis. Antibody titer data from the LIPS
mixture test was plotted against the sum of the titer of the individual Ro52, Ro60, La, Sm-D3, RNP-A and RNP-70k autoantibody titers. Each circle
represents an individual patient. Using the Spearman rank test, the correlation between the two tests was R=0.95.
doi:10.1371/journal.pone.0032001.g003
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Autoantibodies are important elements in both the diagnosis
and monitoring of SLE, as some antibodies appear before the
onset of clinical symptoms and others are associated with specific
clinical manifestations [1,24]. In this study, we employed the liquid
phase LIPS assay, based on luciferase-tagged antigens, to generate
quantitative autoantibody profiles against major SLE autoanti-
gens, IFNs and neuronal proteins. Remarkably, we found two
major autoantibody clusters in SLE consisting of a Sm/RNP
cluster and a Ro/La cluster. Using our highly sensitive LIPS assay
and a simple segregation algorithm based on relative autoantibody
titers, 88% of the pilot cohort and 98% of a second cohort showed
roughly similar numbers of SLE patients belonging to either one of
these two autoantibody clusters. Another intriguing feature is that
some patients had immunoreactivity to the Sm/RNP cluster
without immunoreactivity against antigens in the Ro/La cluster,
while other SLE patients demonstrated immunoreactivity to the
Ro/La cluster without immunoreactivity against Sm/RNP
antigens. Evaluation of the genetic backgrounds of these select
groups of patients with ‘‘pure’’ autoantibody phenotypes might
prove to be highly informative.
A previous study by To and Petri identified three autoantibody
clusters from analysis of seven antigens, including Sm, RNP,
dsDNA, lupus anticoagulant (LAC), cardiolipin (CL), Ro and La
[11]. In their study, the researchers used standard immunoassays
for evaluating autoantibodies and a K-means clustering bioinfor-
matics strategy for analysis. [11]. Three autoantibody clusters were
identified and assignment to each cluster was based on K-means
clustering analysis. This resulted in grouping of patients with
similar autoantibody profiles. Their clusters represented enrich-
ment of particular autoantibodies. For example, in their Sm/RNP
cluster, only a subset of patients, 22.2% and 39.5%, showed
immunoreactivity against Sm and RNP, respectively. In contrast,
our clustering analysis was based on the quantitative measurement
of autoantibody titers using defined recombinant proteins. Despite
these differing approaches, our results confirm two of the three
clusters first observed by To and Petri.
After analyzing six antigens with LIPS in our study, ,90% of
the SLE patients were found to belong to either the Sm/RNP or
Ro/La cluster. Importantly, every SLE patient within a particular
cluster always had immunoreactivity against the relevant antigens.
The clinical significance of our clustering approach revealed that
the Sm/RNP cluster was often associated with the presence of
serositis. While an association between anti-Sm autoantibodies
and serositis has previously been observed in pediatric lupus
populations [25], the association in adult SLE patients has not
been reported. More extensive clinical data, such as the prevalence
of additional hematological abnormalities and sicca symptoms
were not collected here yet may yield further insight into the
clinical significance of the observed autoantibody clusters. The
Ro/La cluster observed here in SLE patients is similar to that of
Sjo ¨gren’s Syndrome, in which 75% of the patients also show
autoantibodies against Ro52, Ro60 and La [26]. Since 5/6
autoantigens used for clustering represent known RNA binding
proteins, further understanding the details of these RNA-binding
proteins and pathways may lead to additional insights into the
mechanisms and/or triggers involved in both SLE and SjS.
Based on the available patient information, two interesting
clinical correlations emerged from our analysis of LIPS serological
profiles outside the autoantibody clusters. First, within the cohort
at large, anti-RNP-70k autoantibodies were significantly associated
with musculoskeletal manifestations, and anti-RNP-70k, RNP-A
and Sm autoantibodies with mucocutaneous symptoms. To our
knowledge, the association of these autoantibodies with mucocu-
taneous symptoms has not yet been reported, but anti-RNP
autoantibodies have previously been associated with musculoskel-
etal symptoms in African-American patients [27] and with
Raynaud’s phenomenon in Chinese patients [28]. While an
association between the Ro/La patient cluster and an increased
prevalence of sicca symptoms was observed by To and Petri [11],
the prevalence of sicca symptoms was not available for this cohort.
Since primary SjS patients also have high titer autoantibodies to
Ro52, Ro60 and La, future large scale genetic studies may
provide additional clues to the similarities and differences
between SjS and SLE patients within the Ro/La autoantibody
cluster. The lack of clinical correlates with our autoantibody SLE
data also suggests that these major diagnostic SLE antigens are
likely not to be informative for identifying patients with
pulmonary, renal, CNS, and hematologic symptoms. It is likely
that the inclusion of other organ-specific antigens would be
needed to identify clinically relevant subtypes. For example, a-
actinin, might be incorporated in LIPS testing to identify patients
with lupus nephritis [29]. Future studies expanding the antigen
panels in the LIPS format to more comprehensively target
specific organ systems may yield additional insight into the full
range of lupus symptomatology.
Elevated levels of interferon proteins and/or activity are
associated with up-regulation of interferon-inducible genes and
are thought to contribute to the pathophysiology of SLE [30].
Seropositive anti-IFN-v autoantibodies were detected in 29% and
38% of the SLE patients in the pilot and second cohort,
respectively. These autoantibodies have been observed in previous
studies of SLE but at much lower frequencies, most likely due to
limitations of the detection methods employed [31,32,33,34]. Anti-
IFN-v autoantibodies have been reported in several other
autoimmune diseases, including in late-onset myasthenia gravis,
and are associated with mutations in the autoimmune regulator
(AIRE) gene in autoimmune polyendocrine syndrome type 1 [35].
Together, these observations suggest that anti-IFN-v autoanti-
bodies may play a role in immune mediated disease. Anti-IFN-v
positive patients also had significantly higher titers of anti-Sm,
RNP-A and RNP-70k autoantibodies and were more frequently
positive for anti-dsDNA in comparison to those patients without
anti-IFN-v autoantibodies, suggesting an overall increased
autoantibody burden in this group.
In our study, a significantly higher prevalence of anti-IFN-a
autoantibodies was detected in the SACQ group in comparison to
the rest of the SLE cohort. These results are consistent with
previous studies demonstrating an inverse relationship between
disease activity and the presence of anti-IFN-a autoantibodies
[31,34]. However, unlike previous groups who did not detect
antibody titer differences in core SLE antigens between anti-IFN-a
positive and negative groups [31], we detected significantly higher
anti-Sm and RNP-A titers in the anti-IFN-a positive group. These
results suggest that despite their clinical phenotype, this subset of
patients has a significantly higher autoantibody burden and
supports recent data of a protective effect of anti-IFN-a antibodies
in SLE [31]. Interestingly, a recent study demonstrated clinical
efficacy for treating SLE with a monoclonal anti-IFN-a antibody
therapy [36,37]. These results are consistent with our findings that
endogenous anti-IFN-a autoantibodies may dampen immune
activation and be correlated with a favorable phenotype. Future
studies of larger patient cohorts employing this simple LIPS test to
detect anti-INF-a autoantibodies in longitudinal samples in
parallel with clinical outcomes are needed to substantiate whether
these autoantibodies have any role in modulating the clinical
outcome of these patients.
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individual nuclear and extractable antigen tests which can be
costly in terms of both time and money. One potential technical
advance was our ability to test a mixture of SLE antigens quickly
and cheaply with LIPS. In our study, a single LIPS test
simultaneously evaluating six autoantigens demonstrated 83%
sensitivity and 93% specificity. Ironically, our mixture employed
only one autoantigen, Sm, which is part of the diagnostic criteria
for SLE. It is highly likely that the inclusion of additional
autoantigens could further improve this LIPS mixture format for
the diagnosis of SLE and is consistent with our previous studies
which utilized antigen mixtures to diagnose various infectious
diseases [22,23]. While combining SLE antigens in the LIPS
mixture format is a practical approach for testing, it alone would
not be sufficient to diagnose SLE because these autoantibodies are
also present in other rheumatological diseases. Furthermore,
additional validation and standardization is needed for the LIPS
assay before it could be used clinically for diagnosis of SLE.
In summary, we report the presence of two distinct autoanti-
body clusters in SLE. The ability to segregate most SLE patients
into two clusters was based on quantitative serological profiles and
relatively simple analysis. One important clinical feature of the
Sm/RNP cluster was an increased prevalence of serositis. In
addition, we identified a link between anti-interferon-a autoanti-
bodies and SACQ, a less severe form of SLE. Future studies with a
larger number of SLE patients and with extensive clinical
background, are needed to further validate the clinical significance
of these findings.
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